Overview
Compare with Korro Bio, Inc., Heat Biologics or Immunome Inc., or pick any stock.
- TickerKYNB on Nasdaq1
- IndustryPharmaceutical Preparations1
- HeadquartersSan Francisco, California1
- Business address350 Bay Street, Suite 100 #6009, San Francisco, Ca 941332
- Filer categoryNon-accelerated filer, Smaller reporting company2
See how the biggest companies compare on our leaderboards
Kyntra Bio, Inc. (“Kyntra Bio” or the “Company”) is a biopharmaceutical company focused on development of novel therapies at the frontiers of cancer biology and anemia.4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Drug Product Revenue brought in 91% of the revenue KYNTRA BIO, INC. broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2024 | 2025 |
|---|---|---|
| Drug Product Revenue | $27.7M | $5.8M |
| Other Revenue - Contract Manufacturing | $1.9M | $592.0K |
Regions
Europe brought in 88% of the revenue KYNTRA BIO, INC. broke down this way in fiscal 2025.
Regions by year
| Regions | 2024 | 2025 |
|---|---|---|
| Europe | $6.3M | $5.6M |
| Japan | -$2.9M | $797.0K |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue0¢$556.0K
- Research and development10¢$23.5M
- Selling, general and admin11¢$27.7M
- Interest4¢$8.8M
- Income tax0¢$90.0K
- Profit75¢$183.5M
Out of $6.4M in revenue.5
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Total revenue | $6.4M | $29.6M |
| Cost of goods sold | $556.0K | $15.6M |
| Research and development | $23.5M | $95.7M |
| Selling, general and administrative | $27.7M | $49.3M |
| Restructuring charge | $553.0K | $19.5M |
| Total operating costs and expenses | $52.3M | $180.0M |
| Loss from operations | -$45.9M | -$150.4M |
| Interest expense | -$8.8M | -$8.2M |
| Loss on debt extinguishments | -$6.6M | $0 |
| Interest income and other income (expenses), net | $2.9M | $5.3M |
| Total interest and other, net | -$12.4M | -$3.0M |
| Loss from continuing operations before income taxes | -$58.3M | -$153.4M |
| Benefit from income taxes | -$90.0K | -$269.0K |
| Loss from continuing operations | -$58.2M | -$153.1M |
| Income from discontinued operations, net of tax | $241.7M | $105.5M |
| Net income (loss) | $183.5M | -$47.6M |
| Loss from continuing operations per share - basic | -$14 | -$38 |
| Loss from continuing operations per share - diluted | -$14 | -$38 |
| Income from discontinued operations per share - basic | $60 | $26 |
| Income from discontinued operations per share - diluted | $60 | $26 |
| Net income (loss) per share - basic | $45.37 | -$11.89 |
| Net income (loss) per share - diluted | $45.37 | -$11.89 |
| Basic | 4.0M shares | 4.0M shares |
| Diluted | 4.0M shares | 4.0M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.5
| Period ending | 2025-12-31 | 2025-06-30 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $47.9M | $50.5M | ||
| Short-term investments | $41.1M | $0 | ||
| Accounts receivable, net | $216.0K | $481.0K | ||
| Inventories | $3.7M | $3.2M | ||
| Prepaid expenses and other current assets | $6.1M | $31.5M | ||
| Current assets held for sale | $0 | $110.8M | ||
| Total current assets | $99.1M | $196.5M | ||
| Long-term investments | $20.2M | $0 | ||
| Other assets | $361.0K | $1.4M | ||
| Long-term assets held for sale | $0 | $16.6M | ||
| Total assets | $119.6M | $214.5M | ||
| Accounts payable | $3.7M | $5.1M | ||
| Accrued and other current liabilities | $20.2M | $62.0M | ||
| Deferred revenue | $5.3M | $27.3M | ||
| Current liabilities held for sale | $0 | $38.9M | ||
| Total current liabilities | $29.2M | $133.3M | ||
| Product development obligations | $19.6M | $17.0M | ||
| Deferred revenue, net of current | $255.0K | $114.7M | ||
| Senior secured term loan facilities, non-current | $0 | $73.1M | ||
| Liability related to sale of future revenues, non-current | $66.0M | $58.9M | ||
| Other long-term liabilities | $82.0K | $822.0K | ||
| Long-term liabilities held for sale | $0 | $356.0K | ||
| Total liabilities | $115.1M | $398.2M | ||
| Redeemable non-controlling interests | $21.5M | $21.5M | ||
| Common stock, $0.01 par value; 225,000 shares authorized at December 31, 2025 and 2024; 4,047 and 4,037 shares issued and outstanding at December 31, 2025 and 2024 | $1.0M | $1.0M | ||
| Additional paid-in capital | $1.7B | $1.7B | ||
| Accumulated other comprehensive loss | -$2.2M | -$5.7M | ||
| Accumulated deficit | -$1.7B | -$1.9B | ||
| Total stockholders' deficit attributable to Kyntra Bio | -$30.0M | -$225.6M | ||
| Nonredeemable non-controlling interests | $13.0M | $20.5M | ||
| Total deficit | -$17.0M | -$205.1M | -$183.7M | |
| Total liabilities, redeemable non-controlling interests and deficit | $119.6M | $214.5M | ||
| Preferred stock, par value | $0.01 | $0.01 | ||
| Preferred stock, shares authorized | 125.0M shares | 125.0M shares | ||
| Preferred stock, shares issued | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding | 0 shares | 0 shares | ||
| Common stock, par value | $0.01 | $0.01 | ||
| Common stock, shares authorized | 225.0M shares | 4.0M shares | 225.0M shares | |
| Common stock, shares issued | 4.0M shares | 4.0M shares | ||
| Common stock, shares outstanding | 4.0M shares | 4.0M shares |
| Period ending | 2025-12-31 | 2025-06-30 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $47.9M | $50.5M | ||
| Short-term investments | $41.1M | $0 | ||
| Accounts receivable, net | $216.0K | $481.0K | ||
| Inventories | $3.7M | $3.2M | ||
| Prepaid expenses and other current assets | $6.1M | $31.5M | ||
| Current assets held for sale | $0 | $110.8M | ||
| Total current assets | $99.1M | $196.5M | ||
| Long-term investments | $20.2M | $0 | ||
| Other assets | $361.0K | $1.4M | ||
| Long-term assets held for sale | $0 | $16.6M | ||
| Total assets | $119.6M | $214.5M | ||
| Accounts payable | $3.7M | $5.1M | ||
| Accrued and other current liabilities | $20.2M | $62.0M | ||
| Deferred revenue | $5.3M | $27.3M | ||
| Current liabilities held for sale | $0 | $38.9M | ||
| Total current liabilities | $29.2M | $133.3M | ||
| Product development obligations | $19.6M | $17.0M | ||
| Deferred revenue, net of current | $255.0K | $114.7M | ||
| Senior secured term loan facilities, non-current | $0 | $73.1M | ||
| Liability related to sale of future revenues, non-current | $66.0M | $58.9M | ||
| Other long-term liabilities | $82.0K | $822.0K | ||
| Long-term liabilities held for sale | $0 | $356.0K | ||
| Total liabilities | $115.1M | $398.2M | ||
| Redeemable non-controlling interests | $21.5M | $21.5M | ||
| Common stock, $0.01 par value; 225,000 shares authorized at December 31, 2025 and 2024; 4,047 and 4,037 shares issued and outstanding at December 31, 2025 and 2024 | $1.0M | $1.0M | ||
| Additional paid-in capital | $1.7B | $1.7B | ||
| Accumulated other comprehensive loss | -$2.2M | -$5.7M | ||
| Accumulated deficit | -$1.7B | -$1.9B | ||
| Total stockholders' deficit attributable to Kyntra Bio | -$30.0M | -$225.6M | ||
| Nonredeemable non-controlling interests | $13.0M | $20.5M | ||
| Total deficit | -$17.0M | -$205.1M | -$183.7M | |
| Total liabilities, redeemable non-controlling interests and deficit | $119.6M | $214.5M | ||
| Preferred stock, par value | $0.01 | $0.01 | ||
| Preferred stock, shares authorized | 125.0M shares | 125.0M shares | ||
| Preferred stock, shares issued | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding | 0 shares | 0 shares | ||
| Common stock, par value | $0.01 | $0.01 | ||
| Common stock, shares authorized | 225.0M shares | 4.0M shares | 225.0M shares | |
| Common stock, shares issued | 4.0M shares | 4.0M shares | ||
| Common stock, shares outstanding | 4.0M shares | 4.0M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net income (loss) | $183.5M | -$47.6M |
| Depreciation | $713.0K | $2.7M |
| Amortization of finance lease right-of-use assets | $35.0K | $38.0K |
| Net accretion of premium and discount on investments | -$72.0K | -$1.7M |
| Investment income in unconsolidated variable interest entity | -$2.5M | -$4.0M |
| Gain on divestiture | -$52.6M | $0 |
| Loss on debt extinguishments | $6.6M | $0 |
| Impairment of property and equipment | $2.1M | $0 |
| Loss on disposal of property and equipment | $0 | $2.6M |
| Stock-based compensation | $6.6M | $25.2M |
| Dividend received from unconsolidated variable interest entity | $3.9M | $2.2M |
| Accounts receivable, net | -$2.5M | -$6.7M |
| Inventories | $5.4M | $22.3M |
| Prepaid expenses and other current assets | $54.1M | -$15.6M |
| Operating lease right-of-use assets | $808.0K | $66.3M |
| Other assets | -$902.0K | $1.0M |
| Accounts payable | -$27.7M | $14.5M |
| Accrued and other liabilities | -$53.5M | -$93.8M |
| Operating lease liabilities, current | -$568.0K | -$12.8M |
| Deferred revenues | -$136.4M | -$28.3M |
| Accrued interest expense related to sale of future revenues | $8.0M | $2.3M |
| Accrued interest for finance lease liabilities | $6.0K | $14.0K |
| Operating lease liabilities, non-current | -$202.0K | -$66.2M |
| Other long-term liabilities | $495.0K | -$540.0K |
| Net cash used in operating activities | -$4.8M | -$138.0M |
| Purchases of property and equipment | -$38.0K | -$266.0K |
| Proceeds from divestiture, net of cash transferred | $96.6M | $0 |
| Proceeds from sale of property and equipment | $0 | $1.0M |
| Purchases of available-for-sale securities | -$61.2M | -$8.6M |
| Proceeds from maturities of investments | $0 | $133.8M |
| Net cash provided by investing activities | $35.4M | $126.0M |
| Repayments of senior secured term loan facilities | -$75.0M | $0 |
| Payment of senior secured term loan facilities pay-off premium and fees | -$5.5M | $0 |
| Repayments of finance lease liabilities | -$10.0K | -$40.0K |
| Cash paid for payroll taxes on restricted stock unit releases | -$69.0K | -$354.0K |
| Cash paid to non-controlling interest | -$5.4M | $0 |
| Payment of issuance cost under ATM Program | -$46.0K | $0 |
| Proceeds from issuance of common stock under employee stock plans | $0 | $139.0K |
| Net cash used in financing activities | -$86.0M | -$255.0K |
| Effect of exchange rate change on cash and cash equivalents | $1.1M | $751.0K |
| Net decrease in cash and cash equivalents | -$54.3M | -$11.5M |
| Holdback consideration receivable related to divestiture in prepaid expenses and other current assets | $4.0M | |
| Interest payments | $7.8M | $16.2M |
| Cash and cash equivalents of continuing operations | $47.9M | $50.5M |
No quarter-by-quarter statement was filed.
Corporate structure
KYNTRA BIO, INC. sits at the top of its group. 6 entities, 3 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of KYNTRA BIO, INC.
- ARMISTICE CAPITAL, LLC Filed SCHEDULE 13G/A on KYNTRA BIO, INC., latest Aug 14, 2026 (9 filings since Feb 14, 2024)
- VANGUARD GROUP INC Filed SCHEDULE 13G/A on KYNTRA BIO, INC., latest Jul 29, 2025 (8 filings since Feb 10, 2022)
- PRIMECAP MANAGEMENT CO/CA/ Filed SCHEDULE 13G/A on KYNTRA BIO, INC., latest Feb 13, 2025 (5 filings since Feb 10, 2022)
- BlackRock Filed SC 13G/A on KYNTRA BIO, INC., latest Jul 8, 2024 (4 filings since Feb 1, 2022)
- Point72 Asset Management, L.P. Filed SC 13G/A on KYNTRA BIO, INC., latest Feb 14, 2024 (3 filings since Feb 10, 2022)
- MILLENNIUM MANAGEMENT LLC Filed SC 13G on KYNTRA BIO, INC., latest Jul 19, 2023
- FIRST TRUST PORTFOLIOS LP Filed SC 13G/A on KYNTRA BIO, INC., latest Feb 8, 2023 (2 filings since Jan 28, 2022)
- KYNTRA BIO, INC. San Francisco, California
- FibroGen China Anemia Holdings, Ltd. Subsidiary · Cayman Islands
- FibroGen Europe Oy Subsidiary · Finland
- FibroGen International (Cayman) Limited Subsidiary · Cayman Islands
- FibroGen INTL LLC Subsidiary · Delaware, United States
- Skin Sciences, Inc. Subsidiary · Delaware, United States
Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What KYNTRA BIO, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $09 Dec 31, 2024 | $117.7M9 Dec 31, 2023 | −100.0% |
| Accumulated depreciation | $09 Dec 31, 2024 | $113.0M9 Dec 31, 2023 | −100.0% |
| Property and equipment, net | $09 Dec 31, 2024 | $4.8M9 Dec 31, 2023 | −100.0% |
| Finance-lease assets | $97.0K9 Dec 31, 2024 | $132.0K9 Dec 31, 2023 | −26.5% |
| Operating-lease assets (leased space) | $09 Dec 31, 2024 | $64.9M9 Dec 31, 2023 | −100.0% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $47.9M5 Dec 31, 2025 | $50.5M5 Dec 31, 2024 | −5.2% |
| Marketable securities, current | $41.1M5 Dec 31, 2025 | $05 Dec 31, 2024 | |
| Debt securities available for sale | $61.3M5 Dec 31, 2025 | $121.9M9 Dec 31, 2023 | −49.7% |
| Long-term investments | $20.2M5 Dec 31, 2025 | $05 Dec 31, 2024 |
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $3.7M5 Dec 31, 2025 | $3.2M5 Dec 31, 2024 | +18.6% |
| Raw materials | $09 Dec 31, 2024 | $787.0K9 Dec 31, 2023 | −100.0% |
| Work in process | $3.2M9 Dec 31, 2024 | $16.4M9 Dec 31, 2023 | −80.7% |
Properties, in its own words
We do not own or lease any physical properties. We currently operate in a fully remote environment, which we believe, combined with contracted services, is sufficient for our operations.
Item 2 of the 10-K filed Mar 16, 2026.4
Leadership
Who has led KYNTRA BIO, INC., and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
201520202025
- Chief executive officerThane Wettig Sep 8, 2023 to now13
- Chief executive officerEnrique A. Conterno Jan 8, 2020 to Jul 10, 202314
- Chief executive officerJames A. Schoeneck Sep 20, 2019 to Sep 20, 201915
- Chief executive officerThomas B. Neff Nov 13, 2014 to Aug 23, 201916
- PresidentJames A. Schoeneck Jan 8, 2020 to Jan 8, 202017
- Chief financial officerDavid Delucia Dec 18, 2024 to now18
- Chief financial officerJuan Graham Sep 9, 2021 to Dec 9, 202419
- Chief financial officerPat Controneo Nov 13, 2014 to Sep 9, 202120
Board members and other officers (25)
- Chief Medical OfficerDeyaa Adib Apr 24, 2024 to Jun 13, 202421
- Chief Commercial OfficerThane Wettig Jun 24, 2020 to Aug 9, 202322
- Incoming Chief Medical OfficerMark Eisner Dec 3, 2020 to Sep 8, 202323
- SVP, China OperationsChristine Chung May 9, 2019 to Mar 7, 202524
- SVP, Clinical Dev, Drug SafetyElias Kouchakji May 9, 2019 to Mar 10, 202125
- Chief Medical OfficerFrank H. Valone Md. Nov 13, 2014 to Apr 4, 201626
- VP, Clinical DevelopmentK. Peony Yu Nov 13, 2014 to Dec 17, 202027
- Board memberMichael Kauffman Jun 6, 2025 to now28
- Board memberThane Wettig Mar 25, 2024 to now29
- Board memberEnrique A. Conterno Jan 8, 2020 to Jul 10, 202314
- Board memberAoife Brennan Aug 7, 2020 to Jun 6, 202430
- Board memberBenjamin Cravatt Aug 7, 2020 to Jun 6, 202431
- Board memberSuzanne Blaug Jun 12, 2019 to Jun 6, 202432
- Board memberMaykin Ho Dec 7, 2018 to now33
- Board memberGerald Lema Sep 21, 2017 to Jun 6, 202434
- Board memberJeffrey William Henderson Aug 13, 2015 to Sep 6, 202335
- Board memberJeffrey L. Edwards Oct 30, 2015 to now36
- Board memberJames A. Schoeneck Nov 13, 2014 to now37
- Board memberJorma Routti Nov 13, 2014 to Mar 27, 201938
- Board memberJulian N. Stern Nov 13, 2014 to Jun 10, 201639
- Board memberKalevi Kurkijarvi Nov 13, 2014 to May 28, 202140
- Board memberMiguel Madero Nov 13, 2014 to Dec 10, 201541
- Board memberThomas B. Neff Nov 13, 2014 to Aug 23, 201916
- Board memberThomas F. Kearns Jr. Nov 13, 2014 to Sep 17, 202142
- Board memberToshinari Tamura Nov 13, 2014 to Jun 7, 201943
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- FibroGen China Anemia Holdings, Ltd. Cayman Islands3
- FibroGen Europe Oy Finland3
- FibroGen INTL LLC Delaware, USA3
- FibroGen International (Cayman) Limited Cayman Islands3
- Skin Sciences, Inc. Delaware, USA3
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Former names
- FIBROGEN INCAug 14, 2002 to Jan 7, 20262
Timeline
- Oct 6, 20268-K Listing notice or transfer44
- Oct 1, 20268-K Executive or director change45
- Aug 31, 20268-K Entered a material agreement; New debt or obligation; Regulation FD disclosure46
- Aug 13, 20268-K Results of operations47
- Jun 16, 20268-K Shareholder vote48
- Jun 9, 20268-K Other events49
- May 11, 20268-K Results of operations50
- Apr 9, 20268-K Listing notice or transfer51
- Mar 16, 20268-K Results of operations52
- Jan 7, 20268-K Bylaws or fiscal year changed; Other events53
- Nov 10, 20258-K Results of operations54
- Nov 6, 20258-K Other events55
- Sep 8, 2023New chief executive Thane Wettig becomes CEO13
- Jan 8, 2020New chief executive Enrique A. Conterno becomes CEO14
- Sep 20, 2019New chief executive James A. Schoeneck becomes CEO15
- Nov 13, 2014New chief executive Thomas B. Neff becomes CEO16
Calendar
Coming up
- Nov 9, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($1.61) a share, on Nov 10, 2025.56
When it reported results
- Aug 13, 2026Reported quarterly or annual results47
- May 11, 2026Reported quarterly or annual results50
- Mar 16, 2026Reported quarterly or annual results52
- Nov 10, 2025Reported quarterly or annual results54
- Aug 11, 2025Reported quarterly or annual results57
- May 12, 2025Reported quarterly or annual results58
- Mar 17, 2025Reported quarterly or annual results59
- Feb 20, 2025Reported quarterly or annual results60
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
342 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 62 major events, 176 insider forms, 32 large holders, 51 other. The latest 20:
- Oct 6, 20264 EDGAR
- Oct 6, 20263 EDGAR
- Oct 6, 20268-K EDGAR
- Oct 1, 20268-K EDGAR
- Sep 9, 20264 EDGAR
- Sep 9, 20264 EDGAR
- Aug 31, 20268-K EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 13, 202610-Q EDGAR
- Aug 13, 20268-K EDGAR
- Jun 17, 20264 EDGAR
- Jun 17, 20264 EDGAR
- Jun 17, 20264 EDGAR
- Jun 17, 20264 EDGAR
- Jun 16, 20268-K EDGAR
- Jun 9, 20264 EDGAR
- Jun 9, 20264 EDGAR
- Jun 9, 20268-K EDGAR
- May 19, 20264/A EDGAR
- May 18, 20264 EDGAR
The 342 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
58 open-market trades by officers, directors and large owners since October 2021: 10 buys and 48 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| May 14, 2026 | Wettig ThaneCEO | Buy | 2,800 | $7.09 | $19.9K | Form 4 |
| May 14, 2026 | Wettig ThaneCEO | Buy | 2,800 | $7.09 | $19.9K | Form 4 |
| Nov 17, 2025 | Wettig ThaneCEO | Buy | 2,700 | $9.10 | $24.6K | Form 4 |
| Nov 13, 2025 | Wettig ThaneCEO | Buy | 1,000 | $9.18 | $9.2K | Form 4 |
| Jun 30, 2025 | Schoeneck James ADirector | Buy | 23,567 | $5.07 | $119.5K | Form 4 |
| Mar 24, 2025 | Wettig ThaneCEO | Buy | 145,000 | $0.35 | $50.8K | Form 4 |
| Mar 21, 2025 | Schoeneck James ADirector | Buy | 50,000 | $0.34 | $17.0K | Form 4 |
| Mar 20, 2025 | Schoeneck James ADirector | Buy | 250,000 | $0.35 | $87.5K | Form 4 |
| Jun 12, 2024 | Adib DeyaaChief Medical Officer | Buy | 22,123 | $1.17 | $25.9K | Form 4 |
| Mar 7, 2024 | Wettig ThaneCEO | Buy | 50,000 | $1.91 | $95.5K | Form 4 |
| Sep 1, 2023 | Henderson Jeffrey WilliamDirector | Sale | 2,000 | $1.03 | $2.1K | Form 4 |
| Aug 4, 2023 | Henderson Jeffrey WilliamDirector | Sale | 2,000 | $1.91 | $3.8K | Form 4 |
| Jul 11, 2023 | Henderson Jeffrey WilliamDirector | Sale | 2,000 | $2.69 | $5.4K | Form 4 |
| Jul 7, 2023 | Conterno Enrique AChief Executive Officer | Sale | 1,880 | $2.80 | $5.3K | Form 4 |
| Jun 23, 2023 | Wettig ThaneCEO | Sale | 791 | $16.53 | $13.1K | Form 4 |
| Jun 14, 2023 | Chung ChristineSVP, CHINA OPERATIONS | Sale | 6,250 | $16.79 | $104.9K | Form 4 |
| Jun 13, 2023 | Chung ChristineSVP, CHINA OPERATIONS | Sale | 6,250 | $17.60 | $110.0K | Form 4 |
| Jun 9, 2023 | Cravatt BenjaminDirector | Sale | 3,944 | $17.17 | $67.7K | Form 4 |
| Jun 9, 2023 | Brennan AoifeDirector | Sale | 4,733 | $17.19 | $81.4K | Form 4 |
| Jun 9, 2023 | Blaug SuzanneDirector | Sale | 8,520 | $17.20 | $146.6K | Form 4 |
All 58 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- ARMISTICE CAPITAL, LLCSCHEDULE 13G/A, 9 filings Feb 14, 2024 to Aug 14, 202661
- VANGUARD GROUP INCSCHEDULE 13G/A, 8 filings Feb 10, 2022 to Jul 29, 202562
- PRIMECAP MANAGEMENT CO/CA/SCHEDULE 13G/A, 5 filings Feb 10, 2022 to Feb 13, 202563
- BlackRockSC 13G/A, 4 filings Feb 1, 2022 to Jul 8, 202464
- Point72 Asset Management, L.P.SC 13G/A, 3 filings Feb 10, 2022 to Feb 14, 202465
- MILLENNIUM MANAGEMENT LLCSC 13G, 1 filing Jul 19, 202366
- FIRST TRUST PORTFOLIOS LPSC 13G/A, 2 filings Jan 28, 2022 to Feb 8, 202367
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Thane Wettig | 61 | $665.0K | $2.1M68 |
| 2025 | Christine L. Chung | $515.0K | $1.2M68 | |
| 2025 | David DeLucia | 37 | $450.0K | $1.1M68 |
| 2024 | Chief Executive Officer | $665.0K | $2.6M68 | |
| 2024 | former Senior Vice PresidentChina Operations | $515.0K | $1.2M68 | |
| 2024 | Chief Financial Officer | $393.5K | $686.2K68 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 27. Change is in shares since the quarter before.
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How KYNTRA BIO, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARKYNTRA BIO, INC.1
- CIK0000921299
- Employer ID (EIN)77-03578274
- Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company4
- Incorporated inDelaware4
- Fiscal year endsDecember 311
- Industry code (SIC)2834 Pharmaceutical Preparations1
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
- Business address350 Bay Street, Suite 100 #6009, San Francisco, CA 941331
- Phone415-978-12001
- Shares outstanding4,049,124 as of Jul 31, 202611
- Public float$21.0M as of Jun 30, 20254
- AuditorPricewaterhouseCoopers LLP, Irvine, California PCAOB ID 238; no auditor attestation of internal control over financial reporting4
- On EDGAR sinceAug 14, 20021
- Filings1,184 in all: 4 (709), 8-K (178), SC 13G/A (41), 10-Q (35), 3 (31), 144 (18), CT ORDER (18), DEFA14A (13)1
All 41 form types
10-K (12), DEF 14A (12), UPLOAD (12), CORRESP (11), SC 13G (10), 4/A (9), SCHEDULE 13G/A (9), REGDEX (8), S-8 (8), 424B5 (5), 5 (5), ARS (5), S-1/A (5), 3/A (4), DRS/A (3), S-3ASR (3), DRSLTR (2), EFFECT (2), SEC STAFF LETTER (2), 10-K/A (1), 10-Q/A (1), 424B4 (1), 5/A (1), 8-A12B (1), 8-K/A (1), CERTNAS (1), D (1), DRS (1), PRE 14A (1), REGDEX/A (1), S-1 (1), S-1MEF (1), S-3 (1)
- Latest filingsAnnual report (10-K) Mar 16, 2026
Quarterly report (10-Q) Aug 13, 2026
Proxy statement (DEF 14A) Apr 27, 2026
Latest 8-K (8-K) Oct 6, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, $0.01 par value | KYNB | The Nasdaq Global Select Market |
From the cover page of the 10-K filed Mar 16, 2026 (Section 12(b) of the Exchange Act).4
Risk factors and legal proceedings
The risks KYNTRA BIO, INC. names in Item 1A of its 10-K filed Mar 16, 2026: 56 risks under these headings, as written.4
- Risks Related to the Development and Commercialization of Our Product Candidates
- We are substantially dependent on the success of our lead products roxadustat and FG-3246 (in conjunction with our PET (as defined below) imaging agent FG-3180).
- Drug development and obtaining marketing authorization are very difficult endeavors, and we may ultimately be unable to obtain regulatory approval for our various product candidates in one or more jurisdictions and in one or more indications.
- Preclinical, Phase 1, and Phase 2 clinical trial results may not be indicative of the results that may be obtained in larger clinical trials.
- We do not know whether our ongoing or planned clinical trials will need to be redesigned based on interim results or if we will be able to achieve sufficient patient enrollment or complete planned clinical trials on schedule.
- Our product candidates may cause or have attributed to them undesirable side effects or have other properties that delay or prevent their regulatory approval or limit their commercial potential.
- Clinical trials of our product candidates may not uncover all possible adverse effects that patients may experience.
- If our manufacturers or we cannot properly manufacture the appropriate volume of product, we may experience delays in development, regulatory approval, launch or successful commercialization.
- Regulatory authorities will do their own benefit risk analysis and may reach a different conclusion than we or our partners have, and these regulatory authorities may base their approval decision on different analyses, data, and statistical methods than ours.
- We face substantial competition in the development and commercialization of product candidates.
- Our product candidates may not achieve adequate market acceptance among physicians, patients, healthcare payors, and others in the medical community necessary for commercial success.
- No or limited reimbursement or insurance coverage of our approved products, by third-party payors may render our products less attractive to patients and healthcare providers.
The other 45 risks
- Risks Related to Our Reliance on Third Parties
- If our collaborations were terminated or if our partners were unwilling or unable to contribute or participate in the collaborations, our ability to successfully develop and commercialize the relevant product candidate could suffer.
- If our preclinical and clinical trial contractors do not properly perform their agreed upon obligations, we may not be able to obtain or may be delayed in receiving regulatory approvals for our product candidates.
- We currently rely, and expect to continue to rely, on third parties to conduct many aspects of our product manufacturing and distribution, and these third parties may terminate these agreements or not perform satisfactorily.
- We may have shortfalls, delays, or excesses in manufacturing.
- Certain components of our products are acquired from single-source suppliers or without long-term supply agreements. The loss of these suppliers, or their failure to supply, would materially and adversely affect our business.
- Risks Related to Our Intellectual Property
- If our efforts to protect our proprietary and exclusively licensed technologies are not adequate, we may not be able to compete effectively in our market.
- Intellectual property disputes may be costly, time consuming, and may negatively affect our competitive position.
- Our reliance on third parties and agreements with collaboration partners requires us to share our trade secrets, which increases the possibility that a competitor may discover them or that our trade secrets will be misappropriated or disclosed.
- The cost of maintaining our patent protection is high and requires continuous review and diligence. We may not be able to effectively maintain our intellectual property position throughout the major markets of the world.
- The laws of some foreign countries do not protect proprietary rights to the same extent as do the laws of the U.S., and we may encounter significant problems in securing and defending our intellectual property rights outside the U.S.
- Intellectual property rights do not address all potential threats to any competitive advantage we may have.
- The existence of counterfeit pharmaceutical products in pharmaceutical markets may compromise our brand and reputation and have a material adverse effect on our business, operations and prospects.
- Risks Related to Government Regulation
- The regulatory approval process is highly uncertain and we may not obtain regulatory approval for our product candidates.
- Our current and future relationships with customers, physicians, and third-party payors are subject to healthcare fraud and abuse laws, false claims laws, transparency laws, and other regulations. If we are unable to comply with such laws, we could face substantial penalties.
- We are subject to stringent and evolving U.S. and foreign laws, regulations, rules, contractual obligations, industry standards, policies and other obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation (including class claims) and mass arbitration demands; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse business consequences.
- We are subject to laws and regulations governing corruption, which require us to maintain costly compliance programs.
- If we fail to maintain an effective system of internal control, it may result in material misstatements in our financial statements.
- The impact of U.S. healthcare reform may adversely affect our business model.
- Roxadustat is considered a Class 2 substance on the 2019 World Anti-Doping Agency Prohibited List that could limit sales and increase security and distribution costs for our partners and us.
- Our employees may engage in misconduct or improper activities, which could result in significant liability or harm our reputation.
- If we fail to comply with environmental, health or safety laws and regulations, we could incur fines, penalties or other costs.
- International Risks
- Within the next year, we may face costs from the wind-up of the Cayman Subsidiary (as defined below), and may not receive some of the AZ Holdbacks (as defined below) related to the sale of FibroGen International and its subsidiaries.
- Changes in U.S. and China relations, as well as relations with other countries, and/or regulations may adversely impact our business.
- We depend on third party suppliers in China, and there are risks inherent to utilizing third-party manufacturing facilities.
- There is a risk of manufacturing disruption due to geopolitical tensions in China and related to U.S. legislation impacting WuXi AppTec, WuXi Biologics, and WuXi XDC.
- We may be subject to currency exchange rate fluctuations and currency exchange restrictions with respect to our partner’s operations in Japan and Europe, which could adversely affect our financial performance.
- We may be subject to tax inefficiencies associated with our offshore corporate structure.
- Risks Related to the Operation of Our Business
- We have incurred significant losses since our inception and anticipate that we will continue to incur losses for the foreseeable future and may never achieve or sustain profitability. We may require additional financing in order to fund our operations, which may be dilutive to our shareholders, restrict our operations or require us to relinquish rights to our intellectual property or product candidates. If we are unable to raise capital when needed or on acceptable terms, we may be forced to delay, reduce or eliminate our research and development programs and/or our commercialization efforts.
- We may be required to recognize an impairment of our long-lived assets, which could adversely affect our financial performance.
- Our non-dilutive transaction with NovaQuest could limit cash flow available for our operations, expose us to risks that could adversely affect our business, financial condition and results of operations, and contain various covenants and other provisions, which, if violated, could result in the acceleration of payments due in connection with such transaction or the foreclosure on security interest.
- We may encounter difficulties in managing our growth and expanding our operations, successfully.
- We are exposed to the risks associated with litigation, investigations, regulatory proceedings, and other legal matters, any of which could have a material adverse effect on us.
- If product liability lawsuits are brought against us, we may incur substantial liabilities and may have to limit commercial operations.
- Our business and operations would suffer in the event of computer system failures.
- If our information technology systems or data, or those of third parties upon which we rely, are or were compromised by a cybersecurity incident, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse consequences.
- Our third party service providers may be exposed to natural disasters and other catastrophes.
- Risks Related to Our Common Stock
- The market price of our common stock may be highly volatile, and you may not be able to resell your shares at or above your purchase price.
- We are a smaller reporting company, and the reduced disclosure requirements applicable to us may make our common stock less attractive to investors.
- We may engage in acquisitions that could dilute stockholders and harm our business.
- Provisions in our charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others and may prevent attempts by our stockholders to replace or remove our current directors or management.
- Changes in our tax provision or exposure to additional tax liabilities could adversely affect our earnings and financial condition.
- Tariffs or other trade policy changes could harm our business.
- Our certificate of incorporation designates courts located in Delaware as the sole forum for certain proceedings, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.
- We do not plan to pay dividends. Capital appreciation will be your sole possible source of gain, which may never occur.
- Our business or our share price could be negatively affected as a result of shareholder proposals or actions.
Legal proceedings
We are a party to various legal actions that arose in the ordinary course of our business. We recognize accruals for any legal action when we conclude that a loss is probable and reasonably estimable. We did not have any material accruals for any legal proceedings in our consolidated balance sheet as of December 31, 2025, as we could not predict the ultimate outcome of these matters, or reasonably estimate any possible loss or range of loss. For a discussion of our legal proceedings, refer to Note 11, Commitments and Contingencies, to the consolidated financial statements.
The opening of Item 3, Legal Proceedings.4
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17SEC EDGARJames A. Schoeneck, President
- 18
- 19SEC EDGARJuan Graham, Chief financial officer
- 20
- 21SEC EDGARDeyaa Adib, Chief Medical Officer
- 22
- 23
- 24
- 25
- 26
- 27
- 28SEC EDGARMichael Kauffman, Board member
- 29SEC EDGARThane Wettig, Board member
- 30SEC EDGARAoife Brennan, Board member
- 31SEC EDGARBenjamin Cravatt, Board member
- 32SEC EDGARSuzanne Blaug, Board member
- 33SEC EDGARMaykin Ho, Board member
- 34SEC EDGARGerald Lema, Board member
- 35
- 36SEC EDGARJeffrey L. Edwards, Board member
- 37SEC EDGARJames A. Schoeneck, Board member
- 38SEC EDGARJorma Routti, Board member
- 39SEC EDGARJulian N. Stern, Board member
- 40SEC EDGARKalevi Kurkijarvi, Board member
- 41SEC EDGARMiguel Madero, Board member
- 42SEC EDGARThomas F. Kearns Jr., Board member
- 43SEC EDGARToshinari Tamura, Board member
- 44SEC EDGARListing notice or transfer
- 45SEC EDGARExecutive or director change
- 46
- 47SEC EDGARResults of operations
- 48SEC EDGARShareholder vote
- 49SEC EDGAROther events
- 50SEC EDGARResults of operations
- 51SEC EDGARListing notice or transfer
- 52SEC EDGARResults of operations
- 53
- 54SEC EDGARResults of operations
- 55SEC EDGAROther events
- 56NasdaqNasdaq calendar
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68